Since alisertib shifts the anti-proliferative curve to the left significantly with either VCR or pan-PI3K inhibition, the addition of anti-PD-L1 completes the blocking of the immune inhibitory loop enhancing the anti-tumor response in PTCL. This evidence concerns the gene CD274 and neoplasm.